Heather Queen-Williams
Psychiatry · Akron, OHNPI 1427146679
Payments from drug & device makers
Across 386 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$869
- AbbVie$735
- Neurocrine Biosciences, Inc.$532
- plus $1K from 9 others
What the payments were for
- Food & beverage$7,195100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 65 | $1,375 |
| Johnson & Johnson | 62 | $1,273 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,005 |
| Lundbeck LLC | 53 | $869 |
| AbbVie(2 entities) | 36 | $735 |
| Neurocrine Biosciences, Inc. | 24 | $532 |
| E.r. Squibb & Sons, L.L.C. | 10 | $376 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $330 |
| Teva Pharmaceuticals USA, Inc. | 22 | $273 |
| Vanda Pharmaceuticals Inc. | 10 | $193 |
| Indivior Inc. | 7 | $128 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Noven Therapeutics, LLC | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$458
- LYBALVI$418
- INVEGA SUSTENNA$251
- COBENFY$248
- ARISTADA INITIO$115
- VRAYLAR$114
How this compares
$7,212 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 63 | $170,291 |
| Abilify MaintenaAripiprazole | 26 | $69,516 |
| VraylarCariprazine Hcl | 30 | $43,454 |
| Seroquel XrQuetiapine Fumarate | 28 | $15,215 |
| Clozapine | 59 | $4,247 |
| Asenapine Maleate | 12 | $2,207 |
| Olanzapine OdtOlanzapine | 28 | $1,663 |
| Aripiprazole | 43 | $1,613 |
| Risperidone | 130 | $1,590 |
| Olanzapine | 43 | $1,466 |
| Paliperidone ErPaliperidone | 16 | $1,431 |
| Oxcarbazepine | 16 | $987 |
| Quetiapine Fumarate | 61 | $909 |
| Hydroxyzine Pamoate | 55 | $512 |
| Ziprasidone Hcl | 31 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,273 | $170,29163 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,005 | $69,51626 claims |
| AbbVieVraylar | $735 | $43,45430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Akron
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.